This study aims to pilot test a virtual mindfulness meditation program for pulmonary hypertension (PH) in preparation for larger testing. Individuals living with PH will be invited to learn mindfulness practices via videos and the MMPH app for 8 weeks.

They will provide feedback via surveys at four time points: before and after the intervention (PAHSS, EmPHass-10, PHQ-8, PCL-5, CAMS-R), and again 1 month and 2 months after. They will be asked to wear a wrist actigraphy device before and after the intervention.

Participants will provide their feedback via an interview about their experience after the intervention is complete.

This study is evaluating a program designed to support adults recovering from a traumatic injury, such as a motor vehicle crash, fall, or other serious injury. Recovery after an injury can be challenging, particularly for people who are experiencing emotional distress as well as difficulties with needs such as housing, food, transportation, or finances. The program, called TRRP+, combines mental health support with assistance from a Community Health Worker who can help participants identify needs, connect with available resources, and navigate services during their recovery. The study will include approximately 100 adults who have experienced a traumatic injury and report emotional distress and at least one unmet social need.
Researchers will examine whether TRRP+ is practical and helpful for patients and will gather feedback from participants, Community Health Workers, and trauma center staff about their experiences with the program. The information learned from this study will help researchers understand how programs like TRRP+ can better support patients' emotional, social, and practical needs as they recover from a traumatic injury.

The purpose of this research study is to develop a multiple health behavior change intervention for weight loss and smoking cessation using medication (Naltrexone/Bupropion) and behavior therapy for adults considering bariatric surgery. All participants will receive the intervention (medication + behavior therapy) for four months. Participants will complete an interview at the end of treatment, which will be used to improve the intervention.

A research study at the Medical University of South Carolina is looking at young adults' experiences with alcohol and e-cigarette use during a 4-week study. The study is enrolling adults ages 21 to 29 who use flavored ready-to-drink alcoholic beverages and e-cigarettes. Participants will complete in-person study visits, brief daily electronic diaries, questionnaires, and provide blood and urine samples for research testing. Some participants will be asked to avoid flavored ready-to-drink alcoholic beverages for 2 weeks, while others will continue their usual use. The purpose of the study is to learn whether this type of short-term study procedure is feasible and acceptable, and to better understand patterns of alcohol and e-cigarette use among young adults.

Smell loss has been found to be associated with mortality and neurodegenerative diseases. Unfortunately, there are no current biomarkers for olfactory loss and no specific mechanism to explain exactly how this association occurs. This study aims to uncover more about smell loss and its association with neurodegenerative disease such as Parkinson's disease, Alzheimer's disease, Multiple Sclerosis, and Mild Cognitive Impairment in the early/mild stages of those conditions. Study procedures involve questionnaires, a 40-item scratch and sniff smell test, assessment of cognitive function, blood sample, and nasal mucus and cell samples collected by a physician.

The 16-week main phase of the study is designed to assess the efficacy and safety of the once daily pitolisant, administered orally upon wakening, in comparison to a placebo. This study includes overnight sleep studies. The effects of HBS-301 on excessive daytime sleepiness, fatigue, and cataplexy (NT1 population only) will be examined.

After the main phase period, there is an option to be in the second part of the study, which will span 1 year. During this period, subjects will receive open label of the active drug, HBS-301.

This study is recruiting pediatric patients who have been diagnosed with Favorable Histology Wilms Tumor (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. The goal of the study to improve outcomes within cohorts of FHWT patients with current long-term EFS rates at or below 80% and maintain outcomes despite therapy reduction within cohorts of FHWT patients with current long-term EFS rates at or above 84%. Common side effects of treatment in regards to this study include nausea, vomiting, hair loss, and fatigue (tiredness). Participants will receive the medications through an IV in their arm and orally. Study participation is expected to be approximately 5 years.

This is a randomized, double-blind, placebo-controlled, multicenter, parallel-group
study of the efficacy and safety of 2 weight-based treatment groups of plecanatide
versus placebo in children and adolescent participants 6 to less than 18 years of age with FC. Randomization will be stratified by sex to ensure balance across treatment groups.

Approximately 30 participants will be randomized to each of the Placebo, Low
Dose, and High Dose groups, within age group. Low Dose and High Dose will be
assigned once daily treatments based on the weight of the participant at
randomization to achieve weight-based dosing of 0.025 to 0.05 mg/kg in the Low
Dose treatment group and 0.05 to 0.1 mg/kg in the High Dose treatment group.

The FIORELLO study is for pediatric patients who 1) Have heart failure and left ventricular systolic dysfunction associated with dilated cardiomyopathy or congenital heart disease and 2) Have successfully completed the FIORE trial. Study participants will receive the study drug finerenone, which has not yet been FDA approved for this specific pediatric population. The study will last 9 months and the objective is to show that finerenone in addition to standard of care is safe when given long-term to pediatric patients with left ventricular systolic dysfunction.

This is a pilot study that will be performed to assess whether a series of once weekly in-home visits over a month (total of 4 visits) after discharge from a hospital with a heart failure diagnosis can help reduce re-hospitalization rates. To accomplish this, subjects will perform a once weekly telehealth visit with a heart failure provider and the following will be completed: symptom questionnaires, blood work, and a video of the neck veins to document physical exam once weekly during the study period. The videos and labs will be sent to the remote care team, who can use this data to manage the subject's medications. The study team will collect information regarding the study participant's frequency of hospital readmissions following enrollment.